. Author manuscript; available in PMC: 2021 Jul 9.

Published in final edited form as: Leuk Lymphoma. 2020 Aug 27;61(14):3468–3475. doi: 10.1080/10428194.2020.1811272

Table 3. Survival outcomes based on the kinetics of MRD at TP1 and TP2.

Survival	MRD	kinetics	p-value	Hazards Ratio	95% Confidence Interval
OS	MRD -ve at TP1 vs	MRD -ve at TP2	.615	1.3	0.45-3.79
	MRD -ve at TP1 vs	MRD + ve at TP1 & TP2	.037	2.2	1.05-4.83
EFS	MRD -ve at TP1 vs	MRD -ve at TP2	.470	1.4	0.54-3.77
	MRD -ve at TP1 vs	MRD + ve at TP1 & TP2	.021	2.2	1.13-4.46
RFS	MRD -ve at TP1 vs	MRD -ve at TP2	.626	1.4	0.36-5.43
	MRD -ve at TP1 vs	MRD + ve at TP1 & TP2	.042	2.6	1.03-6.71

OS: overall survival; EFS: event free survival; RFS: relapse free survival; MRD: measurable residual disease; TP1: time point 1; TP2: time point 2.